Trial Profile
Phase II Study of CPX-351 in Combination With Venetoclax in Patients With Acute Myeloid Leukemia (AML)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Jan 2024
Price :
$35
*
At a glance
- Drugs Cytarabine/daunorubicin (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 12 Dec 2023 Results evaluating the combination of CPX-351 with venetoclax in AML, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 30 Nov 2023 According to a Jazz Pharmaceuticals plc media release, data from this trial will be presented at the at the 65th Annual American Society of Hematology (ASH) Annual Meeting from December 9-12.